Reddy, Tejaswini P.
Choi, Dong S.
Anselme, Ann C.
Qian, Wei
Chen, Wen
Lantto, Johan
Horak, Ivan D.
Kragh, Michael
Chang, Jenny C.
Rosato, Roberto R.
Funding for this research was provided by:
Chan Soon Shiong Institute of Advanced Health (AUP-1010-0025)
Breast Cancer Research Foundation (N/A)
Symphogen A/S (NA)
Article History
Received: 26 March 2019
Accepted: 15 April 2020
First Online: 15 May 2020
Ethics approval and consent to participate
: Tissues used to generate the patient-derived xenografts were collected from consenting patients following institutional review board-approved protocols at clinics in the Baylor College of Medicine and Ben Taub General Hospital (Houston, TX, USA), as previously reported [], and at Houston Methodist Hospital Cancer Center (protocol Pro00005346).
: Not applicable, because the present article does not contain any individual person’s data in any form.
: Johan Lantto, Ivan D. Horak, and Michael Kragh are co-inventors on a patent owned by Symphogen A/S that describes the Pan-HER composition. The other authors declare that they have no competing interests.